Literature DB >> 11583316

Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis.

V Sirolli1, L Strizzi, S Di Stante, I Robuffo, A Procopio, M Bonomini.   

Abstract

Activated platelets may engage in dynamic interplay with other blood cells. We examined the evidence for platelet activation and the formation of platelet-erythrocyte aggregates in chronic hemodialysis patients. Circulating activated platelets (P-selectin/CD63-positive platelets) were higher than normal controls (p < 0.001) and further increased during hemodialysis sessions, the increase being higher when patients were dialyzed with cellulosic than with synthetic membranes. We found direct evidence of uremic platelet-erythrocyte adherence in vitro and increased levels of circulating platelet-erythrocyte aggregates in dialysis patients, which represents a new observation in uremia. Platelet-erythrocyte aggregates were subject to further increase during hemodialysis, and again higher levels were found with cellulosic than synthetic membranes. This phenomenon was reproduced in vitro by both ADP and PAF, but not by either complement factor C3a or by heparin concentrations corresponding to those used for clinical hemodialysis. We conclude that platelet-erythrocyte aggregates occur in hemodialysis patients probably owing to a primary platelet activation mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583316

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 2.  Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms.

Authors:  Stefanie Steiger; Jan Rossaint; Alexander Zarbock; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2021-12-14       Impact factor: 10.121

3.  Biomarkers of chronic inflammatory state in uremia and cardiovascular disease.

Authors:  Vincenzo Panichi; Alessia Scatena; Massimiliano Migliori; Valentina Marchetti; Sabrina Paoletti; Sara Beati
Journal:  Int J Inflam       Date:  2012-06-04

4.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

5.  Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases.

Authors:  Justin Lee; Ryan McMillan; Leonidas Skiadopoulos; Vinod Bansal; José Biller; Debra Hoppensteadt; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-14       Impact factor: 2.389

6.  Whole blood platelet aggregation and release reaction testing in uremic patients.

Authors:  Jay Zeck; Jason Schallheim; Susie Q Lew; Louis DePalma
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.